{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Local Control"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"No Evidence of Disease (NED)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Progression of Disease (POD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Relapse/Recurrence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"following a combination of stereotactic radiosurgery and surgical resection for brain metastases; to determine the incidence of the brain injury following the combination therapy. Local control: Absence of radiographic evidence of tumor at the site of therapy constitutes local control of the treated disease.Recurrence in the treated region: The reappearance of tumor on any MRI or CT scan at the site of treatment constitutes recurrent disease at the treated region. Recurrence outside the treated region: The development of new intracranial metastatic foci or leptomeningeal disease constitutes recurrence outside the treated region. Leptomeningeal disease will be documented by a positive CSF cytology, abnormal myelogram or spinal MRI.\n\nNo evidence of disease: Absence of clinical or radiographic evidence of tumor both at the site of therapy and elsewhere in the brain constitutes no evidence of disease.","groups":[{"description":"Stereotactic Radiosurgery: All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases.","id":"OG000","title":"Treatment - Stereotactic Radiosurgery"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Local Control","type":"PRIMARY","unitOfMeasure":"participants"}